medigraphic.com
ISSN 1561-2988 (Print)

2016, Number 1

<< Back Next >>

Rev Cubana Farm 2016; 50 (1)

Consumption of antibiotics measured from sales in drugstores in Santiago de Cali, Colombia

Castro EJ, Molineros GLF

Language: Spanish
References: 53
Page: 68-84
PDF size: 211.34 Kb.


ABSTRACT

Introduction: antibiotics are drugs used in inpatient and outpatient care: however, the latter type of patients is the one more likely to irrationally use these drugs.
Objective: to determine the total consumption of a group of antibiotics by communes in Santiago de Cali from 2010 to 2013.
Methods: the sample size was calculated and sales information was collected from a group of drugstores. The Defined Daily Dose per 1000 inhabitant-days was used, estimating the total consumption and the consumption of each antibiotic for each commune and in various time units. In this way, monthly consumption from 2010 to 2013, weighted annual consumption from 2010 to 2013, weighted consumption of each month of the year and weighed consumption per commune.
Results: the total consumption of antibiotics was 4.3 Defined Daily Dose per 1000 inhabitant-days; the most consumed antibiotic was amoxicillin; the month with highest consumption rate was March 2011; the year of highest consumption was 2011, the month of the year with the highest consumption in the three studied years was December and the commune with the highest consumption was the no. 22.
Conclusions: this study identified the total consumption and the consumption per antibiotics, the months of the year and the communes of highest consumption of antibiotics.


REFERENCES

  1. 1- Organización Mundial de la Salud [sede web]. Centro de prensa. Resistencia a los antimicrobianos. Nota descriptiva No 194. Ginebra: Organización Mundial de la Salud; Marzo de 2012 [acceso 24 de abril de 2012]. [aprox 1 pantalla]. Disponible en: http://www.who.int/mediacentre/factsheets/fs194/es/

  2. 2-Kunin C.M. Resistance to Antimicrobial Drugs aWolrdwide Calamity. Annals of Internal Medicine 1993;118(7):557-561.

  3. 3-Organización Mundial de la Salud [sede web]. Medicamentos: Uso Racional de los Medicamentos. Centro de prensa. Nota descriptiva No 338. Ginebra: Organización Mundial de la Salud; Mayo de 2010 [acceso 2 de octubre de 2011]. [aprox 1 pantalla]. Disponible en: http://www.who.int/mediacentre/factsheets/fs338/es/index.html

  4. 4-Cohen L.M. Epidemiolofy of Drug Resistance: Implications for a Post-Antimicrobial Era. Science. 1992;257(5073):1050-1055.

  5. 5-Institute of Medicine.Microbial threats to health: emergence, detection and Response. Nota descriptiva No 338. Washington DC: National Academics Press;1998.

  6. 6- Strategic Council on Resistance in Europe. Resistance: a sensitive issue, the European Roadmap to Combat Antimicrobial Resistance. Utrecht, the Netherlands: SCORE; 2004.

  7. 7- Hart C.A. Antimicrobial resistance in developing countries. BMJ. 1998;317:647.

  8. 8-Furuya E. Antimicrobial resistant bacteria in the comunity setting. Nature publishing group. 2006:4:36-45.

  9. 9-Castro EJ, Arboleda GJF, Samboni NPA. Prevalencia y Determinantes de Automedicación con Antibióticos en una Comuna de Santiago de Cali, Colombia. Rev Cubana Farm. 2014;48(1):43-54.

  10. 10-Opatowski L, Mandel J, Varon E, Boelle PY, Temime L, Guillemot D. Antibiotic Dose Impact on Resistance Selection in the Comunity: a Mathematical Model ofβ -Lactams and Streptococcus pneumonia. Dinamcs. Antimicrobial Agenta n Chemptherapy. 2010;54(6):2330-2337.

  11. 11-Gotteesman BS, Carmeli Y, Shitrit P, Chowers M. Impact of Quinolone Restriction on Resistance Patterns of Escherechia coli Isolates from Urine by Culture in a Comunity Setting. Clinical Infectious Diseases. 2009;49:869-875.

  12. 12-Mera MR, Miller LA, White A. Antibacteral use and Streptococcus pneumoniae Penicillin Resistance: A Temporal Relationship Model. Microbial Drug Resistance. 2006;12(3):158-163.

  13. 13-Lucet JC, Decre D, Fichelle A, Joly-Guillou ML, Pernet M, Deblancy C. Control of a prolonged outbreak of extended-spectrumβ -Lactamase-producing Enterobacteriaceae in a University Hospital. Clin Infect Dis. 1999;29:1411-1418.

  14. 14-Payares CJ, Martínez E. Implementación de un Programa de Uso Regulado de Antibióticos en 2 Unidades de Cuidados Intensivo Médico-Quirúrgico en un Hospital Universitario de Tercer Nivel en Colombia. Infectio. 2012;16(4):192-198.

  15. 15-Vazquez ME, Pastor E, Bachiller MR, Vazquez MJ, Eiros JM. Variabilidad Geográfica de la Prescripción de Antibióticos en la Población Pediátrica de Castilla y León durante los años 2001 a 2005. Rev Esp Quimioterap. 2006;19(4):342-348.

  16. 16- Marra F, Mak S, Chong M, Patrick D. The Relationship among Antibiotic Consumption, Socioeconómic factors and Climatic Conditions. Can J Infect Dis Med Microbiol. 2010;21(3):99-106.

  17. 17- Pastor GE, Eiros BJM, Mayo IA. Análisis de la Variabilidad Geográfica del Consumo de Antibióticos de uso Sistémico en la Provincia de Valladolid. Medicina General. 2002;45:473-480.

  18. 18-Kiffer CRV, Camargo ECG, Shimakura SE, Ribeiro PJ, Bailey TC, Pignatari ACC, Monteiro AMV. spatial approach for the epidemiology of antibiotic use and resistance in comunity-based studies: the emergence of urban clusters of Escherechia coli quinolone resistance in Sao Paulo, Brasil. International Journal of Health Geographics. 2011;10:17.

  19. 19-Masiero G, Filippini M, Ferech M, Goossens H. Socioeconomic Determinants of Outpatient Antibiotic use in Europe.Int Public Health. 2010;55:469-478.

  20. 20-Vander SRH, Elseviers MM, Ferech M, Blot S, Goossens H. European Surveillance of Antmicrobial Consumption (ESAC): Data Collection Performance and Methodology Approach. Br J Clin Pharmacol. 2004;58:419-428.

  21. 21-Wirtz VJ, Dreser A, Gonzales R. Trends in Antibiotic Utilization in Eight Latin American Countries, 1997-2007. Rev Panam Salud Publica. 2010;27(3):219-225.

  22. 22-Strom BL. Pharmacoepidemiology. 4th ed. University of Pennsylvania, Philadelphia, USA: John Wiley & Sons, Ltd; 2005/

  23. 23-Díaz PM, Díaz MR, Bravo DL, Marhuenda RE. Estudios de Utilización de Medicamentos: revisión. Pharmaceutical Care España 2000;2:3-7.

  24. 24-Álvarez LF. Farmacoepidemiología. Estudios de Utilización de Medicamentos. Parte I: concepto y metodologia. Seguimiento Farmacoterapeútico. 2004;2(3):129-136.

  25. 25-Castro EJ, Patiño CDA, Carabalí VMA. Estudio de Utilización de Antibióticos a partir de las ventas en Droguerías de una Comuna de Santiago de Cali (Colombia). Revista de la Organización de Farmacéuticos Ibero-Latinoamericanos. 2012;22(4):184-191.

  26. 26-Machado AJ, González SD. Dispensación de Antibióticos de Uso Ambulatorio en una Población Colombiana. Rev Salud Pública. 2009;11(5):734-744.

  27. 27-Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Heindrickx E, Suetens C, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): outpatient. Antibiotic use in Europe. Journal of Antimicrobial Chemotherapy. 2006;58:401-407.

  28. 28-Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, Suetens C, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): Outpatient Quinolone use in Europe. Journal of Antimicrobial Chemotherapy. 2006;58:423-427.

  29. 29-Coenen S, Ferech M, Dvorakova K, Hendrickx E, Suetens C, Goossens H. European Surveillance of Antimicrobial Consumption (ESAC): Outpatient Cephalosporine use in Europe. Journal of Antimicrobial Chemotherapy 2006;58:413-417.

  30. 30-Kegel S, Speranza N, Telechea H, Olmos I, Grekzanic A, Giachetto G, Nanni L. Impacto de la Protocoloización de la Profilaxis Antibiotica en la Cesarea en el Centro Hospitalario Pereira Rossell. Rev Med Uruag 2007;23:77-83.

  31. 31-Bavestrello FL, Cabello MA. Impacto de un Programa de Control de Uso de Antimicrobianos. Rev Chil Infect 2002;19(4):220-225.

  32. 32-Galvis C, Mariño A, Monroy J, Posso H. Impacto de una Política de Restricción de Uso de Antibióticos en la Unidad Neonatal del Hospital Militar Central. Rev Fac Med 2008;16(1):19-24.

  33. 33-Bermejo J, Lesnaberes P, Arnesi N, Gianello M, Notario R, Borda N, Gambandé T, Bencomo B. Factores de Riesgo Asociados a Infecciones por Klebsiella pneumoniae resistentes a Ceftacidima. Enferm Infecc Microbiol Clin 2003;21(2):72-76.

  34. 34-Bermejo J, Bencomo B, Arnesi N, Lesnaberes P, Borda N, Notario R. Alta Correlación entre el consumo de Ciprofloxacina y la Prevalencia de Klebsiella pneumoniae Productora de beta-lactamasa de espectro extendido. Rev Chil Infect 2006;23(4):316-320.

  35. 35-Amábile-Cuevas CF., Arredondo-Garcia JL., Cruz A. Rosas I. Fluorquinoloneresistance in Clinical and enviromentalisolates of Escherechiacoli in Mexico City. J Appl Microbiol. 2010;108(1):158-162.

  36. 36-Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S. Maurer J. Class restriction of Cephalosporin use to control total Cephalosporine resistance in nosocomial Klebsiella. JAMA. 1998;280:1233-1237.

  37. 37-Rice LB, Eckstein EC., DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiellapneumoniae isolates recovered at the Cleveland Departament of Veterans Affairs Medical Center. Clin Infect Dis. 1996;23:118-124.

  38. 38-Chow J, Fine M, Shlaes D, Quin JP, Hooper DC, Johnson MP. Enterobacter bacteremia: Clinical features and Emergence of antibiotic Resistance during therapy. Ann Intern Med. 1991;115:585-590.

  39. 39-Hyde TB, Gay K, Stephen DS, Vugia DJ, Pass M, Johnson S. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA. 2001;286(15):1857-1862.

  40. 40-Bergman M, Huikko S, Houvinen P, Paakkari P, Seppala H. Finish Study Group for Antimicrobial Resistance (FiRe Network). Macrolide and Azitromycin use are linked to incresead macrolide resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2006;50(11):3646-3650.

  41. 41-Martin C, Ofotokun I, Rapp R, Empey K, Armitstead J, Pomeroy C, Hoven A, Evans M. Resultados del Programa de Control de Antimicrobianos en un Hospital Universitario. Amj Helath-Syst Pharm 2005;62:732-738.

  42. 42-Instituto Nacional de Vigilancia de Medicamentos y Alimentos [Internet]. Bogotá: [cited 2012Dic 28]; [about 1 screens]. Available from: https://www.invima.gov.co/index.php?option=com_content&view=article&id=792&Itemid=252

  43. 43-World Health Organization.Guidelines for ATC Classification and DDD Assignment 2013. 16 th edition. WHO Collaborating Centre for Drug Statistics Methodology. Geneva: WHO; 2013.

  44. 44-Instituto colombiano de Normas Técnicas y Certificación. Norma Técnica Colombiana NTC-ISO 2859-1. Procedimientos de Muestreo para Inspección por Atributos. Parte 1: Planes de Muestreo Determinados por el Nivel Aceptable de Calidad (NAC) para Inspección Lote a Lote. Bogotá: Icontec; 2002.

  45. 45-Pedrera V, Schwarz H, Pascual TM, Gil GV, Orozco D, Canelles JM. Análisis del Consumo de Antibióticos en la Comunidad Valenciana durante los años 2000-2002. Enferm Infecc Microbiol Clin 2004;22(7):385-389.

  46. 46-López GJ, Mena BM, Mora E. Estudio de Utilización de antibióticos en el Servicio de Consulta Externa de un Hospital de Tercer Nivel de la ciudad de Bogotá. Rev Colomb Cienc Quim Farm 2008;37(2):224-240.

  47. 47-Awasthi S. ISCAP Study Group Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentrerandomised controlled trial. BMJ 2004;328:791.

  48. 48-Pastor E, Eiros JM, Mayo A. Descripción del consumo diferencial de Macrolidos por áreas geográficas en la provincia de Valladolid. Enferm Infecc Microbiol Clin 2002;20(10):498-502.

  49. 49-Goossens H. Antibiotic consumption and link to resistance. Clinic Microbiol Infection 2009;15(Suppl 3):12-15.

  50. 50-Organización Panamericana de la Salud [sede web]. Washington: Organización Panamericana de la Salud; junio de 1999 [acceso 7 de agosto de 2011]. Boletín epidemiológico 20 (2): Conferencia Panamericana de Resistencia Antimicrobiana en las Américas [aprox 1 pantalla]. Disponible en: http://www.paho.org/spanish/sha/bs992resist.htm

  51. 51-World Health Organization. WHO Global Strategy for Containment of Antimicrobial Resistance. WHO/CDS/CSR/DRS/2001.2.Geneva: WHO; 2001.

  52. 52-Lonks RJ, Garau J, Gomez L, Xercavins M, Ochoa de EA, Gareen IF, Reiss PT, Medeiros AA. Failure of Macrolide Antibiotic Treatment in Pacients with Bacteremia Due to Erythromycin-Resistant Streptococcus pneumoniae. Clinical Infectious Diseases 2002; 35:556-564.

  53. 53-Bortman M. Elaboración de Corredores o Canales Endémicos mediante planillas de Cálculo. Rev Panam Salud Pública 1999;5(1):1-8.




2020     |     www.medigraphic.com